REVELATION BIOSCIENCES INC (REVB)

Company Profile

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California. The company went IPO on 2020-10-08. Its therapeutic candidates are based on the active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include REVTx-300, which is being developed as a potential therapy for the prevention and treatment of acute organ injury and chronic organ disease; REVTx-100, which is being developed for the prevention and treatment of infections, including healthcare-associated bacterial infections resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, which is being developed as a potential intranasal therapy that is administered with a traditional commercially available intramuscular (IM) vaccine, and REVTx-99b, which is being developed as a treatment for food allergies.

Company Info

REVELATION BIOSCIENCES INC

4660 Lajolla Village Drive, Suite 100

San Diego CALIFORNIA

P: 16508003717.0

Employees: 14

Website: https://www.revbiosciences.com/